BY-102 prodrug

• Treatment for Multiple Sclerosis (MS), an autoimmune disease.
• Multiple sclerosis (MS), also known as encephalomyelitis disseminate, is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a series of deteriorating signs and symptoms, including physical, mental, and sometimes psychiatric problems.
• Specific symptoms can include double vision, blindness in one eye, muscle weakness and trouble with sensation or coordination.
• About 2.5 million people globally have this illness, representations vary widely in different regions and among different populations.
• Every year, about 20,000 people died from MS. Life expectancy of those people who become ill average five to ten years less than those not affected.

The market potential for BY-102 to treat multiple sclerosis is immense!

• The MS market was USD25 billion (about NTD725 billion) in 2019.
• The MS market is expected to reach USD40.66 billion (about NTD1.2 trillion) in 2027.

BY-102 is the blockbuster drug candidate that all global pharmaceutical companies

want to co-develop and have related marketing rights!

Current status

• Pre-clinical preparation
• Expect to start Phase 1 clinical trials in second half of 2023.